December 4, 2023

Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I)

Com a expansão dessa liderança estratégica e operacional, a Zenas se posiciona para o crescimento esperado com o avanço do voltadas para inflamações e imunologia nos ensaios clínicos em estágio avançado de várias indicações potenciais de I&I WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa

Le renforcement du leadership stratégique et opérationnel permet à Zenas de se développer et les essais cliniques en phase avancée sur l’obéxélimab progressent, pour de multiples indications potentielles dans l’I&I WALTHAM, Massachusetts, 04 déc. 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à devenir un leader

A Media Snippet accompanying this announcement is available by clicking on this link. Most successful dinosaur exhibit of all-time More than 1.5 million visitors see Barbara and Peter – a world-first male & female T. rex pairing Barbara is one of only three female T. rex specimens ever discovered Auckland